Friday, March 29, 2024
wellness India Expo
Home Tags Johnson & Johnson

Tag: Johnson & Johnson

J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s...

In 2022, the global ADC market for cancer treatment was valued at $7.5 billion, with Roche’s Kadcyla generating $2.2 billion, followed by Daiichi Sankyo’s Enhertu at $1.5 billion

Johnson & Johnson Medtech India appoints Anuj Virmani as MD

With an exceptional track record of 28 years in the industry, Anuj brings extensive healthcare experience and a strategic patient-centric vision to lead the company's operations

Johnson & Johnson MedTech India partners with Karkinos to upskill healthcare...

To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform

Digitally powered smart labs are the future of biopharma R&D: Experts

Leading biopharmaceutical scientists and industry leaders shared their valuable insights at the e-Conference on ‘Digital Laboratories: The Emerging Era of High-Tech R&D’ organized by BioVoice News on March 30, 2022

Johnson & Johnson India launches ‘Be The Change For TB’ initiative

Corporate TB Pledge is a joint initiative between Central TB Division, Ministry of Health and Family Welfare and USAID. #BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers

World is on the cusp of making a technological shift: Alex...

mRNA vaccines have been possible because we digitized the genomic information from the virus itself, stated Alex Gorsky, Executive Chairman, Johnson & Johnson.................

Govt clarifies on MDR-TB drug ‘Bedaquiline’ controversy

The union health ministry has clarified that the Bedaquiline which is used in selective cases, is available only through Revised National TB Control Programme (RNTCP) and open market sale of the drug is not permitted in India as of now...…………..

Johnson & Johnson announces progress towards health for humanity goals

The company's annual 'Health for Humanity' report discloses progress on global commitments and highlights key achievements toward eradicating and preventing disease, reimagining care delivery and promoting lifelong health................

Small biotech companies dominate the pipeline for Microbiome-targeted therapies, says GlobalData

GlobalData anticipates ample opportunities for therapies targeting the skin microbiome as there are only three pipeline therapies in clinical development................

Healthcare firms finding obesity market a challenge to penetrate, says GlobalData

The latest failure of three anti-obesity drugs to provide the anticipated results could lead to the companies taking a cautious approach while investing to develop further drugs in the area.............